R-DHAP Followed by Allo-HCT Reasonable for High-risk CLL

Share this content:
R-DHAP followed by allo-HCT is a reasonable treatment option for patients with high-risk chronic lymphocytic leukemia (CLL).
R-DHAP followed by allo-HCT is a reasonable treatment option for patients with high-risk chronic lymphocytic leukemia (CLL).

R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin) followed by allogeneic hematopoietic cell transplantation (allo-HCT) is a reasonable treatment option for patients with high-risk chronic lymphocytic leukemia (CLL) who are resistant to targeted therapies, a study published in the journal Bone Marrow Transplantation has shown.1

Targeted therapies like ibrutinib and idelalisib have revolutionized the treatment of patients with CLL, but allo-HCT remains the only curative option for these patients. Because there is no standard remission-induction regimen for patients with active disease at time of allo-HCT, researchers sought to prospectively assess outcomes after R-DHAP followed by allo-HCT.

 

For the study, researchers enrolled 46 patients who were relapsed/refractory less than 1 year after fludarabine therapy or less than 2 years after fludarabine-based immunochemotherapy or relapsed/refractory with del(17p).

Of those, 29 received 3 or more cycles of R-DHAP and 16 received less than 3 cycles, either due to disease progression, toxicity, or toxic deaths.

Results showed that the overall response rate to R-DHAP was 58%, and 31 patients proceeded to allo-HCT following conditioning with fludarabine and 2 Gy total body irradiation.

Of the 31 patients who underwent transplantation, 20 (65%) were progression-free at 2 years after allo-HCT, including 17 without minimal residual disease.

RELATED: CLL: Allogeneic HCT Lengthens Time to Next Therapy

After a median follow-up of 35.5 months, researchers found that the 2-year progression free survival and overall survival in the intention-to-treat population of 46 patients was 42% and 51%, respectively.

The study also demonstrated that harboring a del(17p) mutation or being refractory to fludarabine had no impact on outcomes in these patients.

Reference

  1. van Gelder M, van Oers MH, Alemayehu WG, et al. Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study [published online ahead of print February 15, 2016]. Bone Marrow Transplant. doi: 10.1038/bmt.2016.9.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters